Federal Health Agencies To Fund Studies On Minor Cannabinoids & Terpenes
Several federal health agencies once again confirmed they will support research into the therapeutic potential of “minor cannabinoids” and cannabis terpenes.
The National Institutes of Health (NIH) together with eight of its component agencies issued a notice of special interest (NOSI) on July 27, with the title “Promoting Mechanistic Research on Therapeutic and Other Biological Properties of Minor Cannabinoids and Terpenes.”
Per the notice, minor cannabinoids are considered any from the marijuana plant other than delta9 THC. Cannabinoids of special interest include delta-8 THC, Cannabidiol (CBD), Cannabigerol (CBG), Cannabinol (CBN), Cannabichromene (CBC), cannabichromevarin (CBDV), tetrahydrocannabivarin (THCV), Tetrahydrocannabivarin acid (THCVA), tetrahydrocannabinolic acid (THCA), carmagerol, cannabicitran, sesquicannabigerol. To date, most of these cannabinoids have been poorly researched.
“This NOSI intends to support highly innovative basic and/or mechanistic studies in appropriate model organisms and/or human subjects aiming to investigate the impact of minor cannabinoids and terpenes on mechanisms underlying their therapeutic effects,” the notice says. “Preclinical studies of combinations of minor cannabinoids with terpenes or other natural products that may enhance their therapeutic benefits and/or abate unwanted effects are encouraged.”